New hope for back pain: drug trial targets ankylosing spondylitis in chinese patients
NCT ID NCT05303285
First seen Jan 28, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study tests if a 300mg dose of secukinumab is safe and effective for Chinese adults with active ankylosing spondylitis (AS), a type of arthritis that causes back pain and stiffness. Participants must have tried at least two NSAIDs without success and never used biologic drugs. The main goal is to see if the drug improves symptoms like pain and function after 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS (AS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of RheumatologyTongji Hospital
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 430030, China
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.